Last month, the DEA enthused the pharmaceutical industry but disappointed cannabis advocates by re-scheduling the drug Epidiolex—but not CBD, the cannabinoid that makes it work. Now word emerges of a letter to the DEA by the Food & Drug Administration essentially calling for the descheduling of CBD altogether.
Recent comments
4 days 22 hours ago
1 week 3 days ago
11 weeks 3 days ago
15 weeks 3 days ago
16 weeks 4 days ago
16 weeks 4 days ago
37 weeks 4 days ago
41 weeks 5 days ago
43 weeks 2 days ago
43 weeks 3 days ago